Ȩ > ±Û·Î¹úÆÄÆ®³Ê > Mellalta Meets LLP

Mellalta Meets LLP

±Û·Î¹úÀÎÆ÷¸ÞÀ̼ÇÀº Mellalta Meets LLPÀÇ Çѱ¹ ÆÄÆ®³ÊÀÔ´Ï´Ù. Mellalta Meets LLP°¡ ¹ßÇàÇÏ´Â ½ÃÀå º¸°í¼­¸¦ ÆǸÅÇÏ°í ÀÖ½À´Ï´Ù.
°Ë»öµÇÁö ¾Ê´Â ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
Melalta Meets´Â ¿¬±¸ ±â¹ÝÀÇ ±Û·Î¹ú ½ÃÀå Á¶»ç ¹× ÄÁ¼³Æà ±â¾÷À¸·Î, Àü ¼¼°èÀÇ ´Ù¾çÇÑ ±â¾÷¿¡°Ô ÃÖÀûÈ­µÈ »ç¾÷ Àü·«À» Á¦°øÇÏ¿© ´õ ³ªÀº »ç¾÷ °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ƯÈ÷ Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï ¸ÂÃãÇü ½ÃÀå º¸°í¼­¸¦ Á¦°øÇÕ´Ï´Ù.
°Ë»ö
Á¦¸ñ°Ë»ö
1 - 16 ¸®ºä (Àüü£º 16 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1517292
¹ßÇàÀÏ
2024³â 07¿ù
ÆäÀÌÁö Á¤º¸
114 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,672,000 (ºÎ°¡¼¼ º°µµ)
Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics 2024
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1474029
¹ßÇàÀÏ
2024³â 05¿ù
ÆäÀÌÁö Á¤º¸
109 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,672,000 (ºÎ°¡¼¼ º°µµ)
Limbal Stem Cell Deficiency (LSCD) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1466820
¹ßÇàÀÏ
2024³â 02¿ù
ÆäÀÌÁö Á¤º¸
156 Pages
°¡°Ý
US $ 7,000 -> £Ü 10,283,000 (ºÎ°¡¼¼ º°µµ)
Corneal Scarring | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1466819
¹ßÇàÀÏ
2024³â 02¿ù
ÆäÀÌÁö Á¤º¸
113 Pages
°¡°Ý
US $ 7,000 -> £Ü 10,283,000 (ºÎ°¡¼¼ º°µµ)
Neurotrophic Keratitis (NK) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1466818
¹ßÇàÀÏ
2024³â 02¿ù
ÆäÀÌÁö Á¤º¸
180 Pages
°¡°Ý
US $ 7,000 -> £Ü 10,283,000 (ºÎ°¡¼¼ º°µµ)
Head and Neck Squamous Cell Carcinoma (HNSCC) - Tumour Deck
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1349830
¹ßÇàÁ¤º¸
¿¬°£±¸µ¶
ÆäÀÌÁö Á¤º¸
300 Pages
°¡°Ý
US $ 11,800 -> £Ü 17,335,000 (ºÎ°¡¼¼ º°µµ)
HER2-Low Metastatic Breast Cancer - Tumour Deck
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1349829
¹ßÇàÁ¤º¸
¿¬°£±¸µ¶
ÆäÀÌÁö Á¤º¸
300 Pages
°¡°Ý
US $ 11,800 -> £Ü 17,335,000 (ºÎ°¡¼¼ º°µµ)
HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1349828
¹ßÇàÀÏ
On Demand Report
ÆäÀÌÁö Á¤º¸
200 Pages
°¡°Ý
US $ 6,989 -> £Ü 10,267,000 (ºÎ°¡¼¼ º°µµ)
HER2-Low Breast Cancer- Pipeline Analytics 2023
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1349827
¹ßÇàÀÏ
On Demand Report
ÆäÀÌÁö Á¤º¸
180 Pages
°¡°Ý
US $ 2,500 -> £Ü 3,672,000 (ºÎ°¡¼¼ º°µµ)
HER2-Low Metastatic Breast Cancer (mBC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1349826
¹ßÇàÀÏ
On Demand Report
ÆäÀÌÁö Á¤º¸
200 Pages
°¡°Ý
US $ 6,989 -> £Ü 10,267,000 (ºÎ°¡¼¼ º°µµ)
Carotid Artery Disease (CAD)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2033 [CEA, CAS & TCAR Procedure Market]
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1307858
¹ßÇàÀÏ
2023³â 06¿ù
ÆäÀÌÁö Á¤º¸
246 Pages
°¡°Ý
US $ 6,989 -> £Ü 10,267,000 (ºÎ°¡¼¼ º°µµ)
Head and Neck Squamous Cell Carcinoma (HNSCC)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1307859
¹ßÇàÀÏ
2023³â 06¿ù
ÆäÀÌÁö Á¤º¸
252 Pages
°¡°Ý
US $ 7,500 -> £Ü 11,018,000 (ºÎ°¡¼¼ º°µµ)
Acute low back pain (ALBP)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1307857
¹ßÇàÀÏ
2023³â 05¿ù
ÆäÀÌÁö Á¤º¸
140 Pages
°¡°Ý
US $ 6,989 -> £Ü 10,267,000 (ºÎ°¡¼¼ º°µµ)
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1268028
¹ßÇàÀÏ
2023³â 05¿ù
ÆäÀÌÁö Á¤º¸
53 Pages
°¡°Ý
US $ 2,900 -> £Ü 4,260,000 (ºÎ°¡¼¼ º°µµ)
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1268029
¹ßÇàÀÏ
2023³â 05¿ù
ÆäÀÌÁö Á¤º¸
61 Pages
°¡°Ý
US $ 3,200 -> £Ü 4,701,000 (ºÎ°¡¼¼ º°µµ)
¸®¼­Ä¡»ç
Mellalta Meets LLP
»óÇ°ÄÚµå
1268027
¹ßÇàÀÏ
2023³â 05¿ù
ÆäÀÌÁö Á¤º¸
240 Pages
°¡°Ý
US $ 3,900 -> £Ü 5,729,000 (ºÎ°¡¼¼ º°µµ)
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦